Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anteris Technologies Global Corp. - Common Stock (NQ:AVR)

4.840 -0.390 (-7.46%)
Streaming Delayed Price Updated: 12:11 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Anteris Technologies Global Corp. - Common Stock

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Announces Results for the Second Quarter of 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities 
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Announces Results for the First Quarter of 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year 
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Reports 2024 Financial Results and Provides Corporate Update
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays
From Anteris Technologies Global Corp.
Via GlobeNewswire
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering
From Anteris Technologies Global Corp.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.